Produits pharmaceutiques
Titre original de l'avis
Italy-Naples: Pharmaceutical products
Score d'opportunité
Pourquoi ce score ?
Opportunité
70 / 100
Complexité
65 / 100
Facteurs de risque
Only the notice and XML data are available; full procurement documents (specifications, contract terms, qualification c...
The high estimated value (€20 billion) is likely to attract many bidders, including large pharmaceutical companies, mak...
Restricted procedure — pre-qualification required
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Informations clés
- Pouvoir adjudicateur
- SOCIETA' REGIONALE PER LA SANITA' (SO.RE.SA. S.P.A.)
- Pays
- Italie
- CPV
- 33600000 - Pharmaceutical products
- Date limite
- Dec 06, 2028
- Valeur estimée
- EUR 20000M
Aperçu
Strong opportunityFaits clés
- EUR 20000M estimated value
- Supplies contract
- Supply of pharmaceutical products including medicines, blood derivatives, vaccines, and similar products.
- Dynamic Purchasing System (DPS) covering healthcare authorities in Campania and potentially other Italian regions.
Afficher le résumé complet
This notice announces the establishment of a Dynamic Purchasing System (DPS) for the supply of pharmaceutical products (medicines, blood derivatives, vaccines, etc.) to healthcare authorities in the Campania region of Italy, with potential extension to other Italian regions. The DPS is managed by So.Re.Sa. S.p.A., the regional purchasing body. The procedure is restricted, and the estimated total value is €20 billion. The deadline for submission of initial tenders is 6 December 2028.
Risques
Only the notice and XML data are available; full procurement documents (specifications, contract terms, qualification c...
The high estimated value (€20 billion) is likely to attract many bidders, including large pharmaceutical companies, mak...
Restricted procedure — pre-qualification required
No procurement documents available
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Administrative
- Submission of tenders via the DPS platform (www.soresa.it).
- Tenders must be submitted in Italian.
- All lots (categories) must be covered in a single submission.
Les exigences peuvent être incomplètes.
Acheteur
Localisation
Naples, ITA
Site web
Profil acheteur
Identifiant
7691971
Activité
General public services
Détails de la procédure
- Date de publication
- 08 Dec 2022
- Langues
- Italian
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 687775-2022
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
70 / 100
Complexité
65 / 100
Facteurs de risque
Only the notice and XML data are available; full procurement documents (specifications, contract terms, qualification c...
The high estimated value (€20 billion) is likely to attract many bidders, including large pharmaceutical companies, mak...
Restricted procedure — pre-qualification required
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications